Arcoma (ARCOMA) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached 31.9 MSEK, down from 35.9 MSEK year-over-year, mainly due to temporary installation delays in North America and weak EMEA demand.

• Aftermarket business grew strongly by 35%, offsetting some primary sales declines.

• EBITDA for Q3 was 4.3 MSEK, nearly flat year-over-year despite lower revenue, reflecting strong cost control and improved gross margin.

• Accumulated 2024 EBITDA more than doubled to 16.6 MSEK from 7.0 MSEK, with pre-tax profit at 10.5 MSEK versus 0.05 MSEK last year.

• No significant events reported during or after the period.

Financial highlights

• Q3 net sales: 31,886 KSEK (35,858 KSEK in Q3 2023); YTD: 120,005 KSEK (111,689 KSEK in 2023).

• Q3 EBITDA: 4,325 KSEK (4,402 KSEK); YTD: 16,573 KSEK (7,037 KSEK).

• Q3 pre-tax profit: 2,303 KSEK (1,978 KSEK); YTD: 10,462 KSEK (46 KSEK).

• Q3 EPS: 0.17 SEK (0.15 SEK); YTD EPS: 0.79 SEK (0.00 SEK).

• Q3 gross margin: 41% (39% in Q3 2023).

Outlook and guidance

• Underlying demand in North America remains strong, with positive momentum expected as installation delays resolve.

• Early signs of increased activity in EMEA, driven by lower interest rate expectations and replacement needs.

• Continued focus on cost control, production efficiency, and margin improvement.